Novartis' Entresto Patent Claims Revived by CAFCThe CAFC upheld the validity of Novartis' Entresto patent claims, emphasizing the importance of the written description standard and rejecting arguments for invalidity.
Disparaging in Context: Motivation to Combine Exists Even For a Markedly Inferior ElementThe Federal Circuit affirmed the PTAB's decision that Novartis's patent claims were unpatentably obvious.
Novartis' Entresto Patent Claims Revived by CAFCThe CAFC upheld the validity of Novartis' Entresto patent claims, emphasizing the importance of the written description standard and rejecting arguments for invalidity.
Disparaging in Context: Motivation to Combine Exists Even For a Markedly Inferior ElementThe Federal Circuit affirmed the PTAB's decision that Novartis's patent claims were unpatentably obvious.
Swiss pharma giant Novartis says 30 pipeline drugs with 'significant potential' will drive long-term growthNovartis increased its mid-term sales growth forecast to 6%, expecting significant advances through pipeline assets and peak sales of key medications.